Syndax Ebit from 2010 to 2024
| SNDX Stock | USD 16.73 0.64 3.98% |
EBIT | First Reported 2012-12-31 | Previous Quarter -68 M | Current Value -84.1 M | Quarterly Volatility 26.6 M |
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
Syndax | Ebit |
Latest Syndax Pharmaceuticals' Ebit Growth Pattern
Below is the plot of the Ebit of Syndax Pharmaceuticals over the last few years. It is Syndax Pharmaceuticals' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Syndax Ebit Regression Statistics
| Arithmetic Mean | (64,753,487) | |
| Geometric Mean | 39,735,078 | |
| Coefficient Of Variation | (118.76) | |
| Mean Deviation | 56,493,182 | |
| Median | (43,766,000) | |
| Standard Deviation | 76,898,888 | |
| Sample Variance | 5913.4T | |
| Range | 256.2M | |
| R-Value | (0.74) | |
| Mean Square Error | 2871T | |
| R-Squared | 0.55 | |
| Significance | 0 | |
| Slope | (12,742,604) | |
| Total Sum of Squares | 82788.1T |
Syndax Ebit History
Other Fundumenentals of Syndax Pharmaceuticals
About Syndax Pharmaceuticals Financial Statements
Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -230 M | -218.5 M | |
| EBITDA | -229.9 M | -218.4 M | |
| Ebt Per Ebit | 0.91 | 1.17 | |
| Ebit Per Revenue | 0.17 | 0.18 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.